中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
5期
659-660
,共2页
醛氢叶酸%氟尿嘧啶%顺铂%食管癌%化学疗法
醛氫葉痠%氟尿嘧啶%順鉑%食管癌%化學療法
철경협산%불뇨밀정%순박%식관암%화학요법
LV%5-Fu%DDP%Esophageal cancer,chemotherapy
目的 观察大剂量醛氢叶酸(Leucovorin,LV)加氟尿嘧啶(5-Fluorouracil,5-Fu)持续48 h滴注联合顺铂(Cisplantin,DDP)治疗晚期食管癌与传统DF方案疗效及其不良反应的差别.方法 病理确诊的食管癌60例,随机分成治疗组30例,采用DDP 25 mg/m2静脉滴注30 min,第1～3天；LV 200 mg/m2静脉滴注2h,5-Fu 0.5静脉注射10 min,然后5-Fu 2.5/m2,用输液泵连续输注48 h,每21天重复,2个周期以上评定疗效.对照组30例,采用DDP 25mg/m2静脉滴注30 min,第1～3天；LV 60 mg/m2静脉滴注2h,第1～5天,5-Fu 500 mg/m2静脉滴注8h,每21天重复,2个周期以上评定疗效.结果 近期疗效,治疗组,完全缓解(CR)1例,部分缓解(PR)15例,稳定(SD)9例,进展(PD)5例,总有效率CR+ PR53.3％(16/30).对照组,PR 11例,SD 11例,PD 8例,无PR病例,总有效率36.7％(11/30).恶心、呕吐、口腔粘膜炎、骨髓抑制、腹泻及脱发为主要不良反应.两组均能耐受,未发生Ⅳ度毒性,骨髓抑制对照组比治疗组明显.结论 大剂量LV+ 5-Fu 48 h滴注联合铂治疗晚期食管癌近期疗效较传统DF方案好,不良反应较小,值得进一步扩大研究.
目的 觀察大劑量醛氫葉痠(Leucovorin,LV)加氟尿嘧啶(5-Fluorouracil,5-Fu)持續48 h滴註聯閤順鉑(Cisplantin,DDP)治療晚期食管癌與傳統DF方案療效及其不良反應的差彆.方法 病理確診的食管癌60例,隨機分成治療組30例,採用DDP 25 mg/m2靜脈滴註30 min,第1～3天；LV 200 mg/m2靜脈滴註2h,5-Fu 0.5靜脈註射10 min,然後5-Fu 2.5/m2,用輸液泵連續輸註48 h,每21天重複,2箇週期以上評定療效.對照組30例,採用DDP 25mg/m2靜脈滴註30 min,第1～3天；LV 60 mg/m2靜脈滴註2h,第1～5天,5-Fu 500 mg/m2靜脈滴註8h,每21天重複,2箇週期以上評定療效.結果 近期療效,治療組,完全緩解(CR)1例,部分緩解(PR)15例,穩定(SD)9例,進展(PD)5例,總有效率CR+ PR53.3％(16/30).對照組,PR 11例,SD 11例,PD 8例,無PR病例,總有效率36.7％(11/30).噁心、嘔吐、口腔粘膜炎、骨髓抑製、腹瀉及脫髮為主要不良反應.兩組均能耐受,未髮生Ⅳ度毒性,骨髓抑製對照組比治療組明顯.結論 大劑量LV+ 5-Fu 48 h滴註聯閤鉑治療晚期食管癌近期療效較傳統DF方案好,不良反應較小,值得進一步擴大研究.
목적 관찰대제량철경협산(Leucovorin,LV)가불뇨밀정(5-Fluorouracil,5-Fu)지속48 h적주연합순박(Cisplantin,DDP)치료만기식관암여전통DF방안료효급기불량반응적차별.방법 병리학진적식관암60례,수궤분성치료조30례,채용DDP 25 mg/m2정맥적주30 min,제1～3천；LV 200 mg/m2정맥적주2h,5-Fu 0.5정맥주사10 min,연후5-Fu 2.5/m2,용수액빙련속수주48 h,매21천중복,2개주기이상평정료효.대조조30례,채용DDP 25mg/m2정맥적주30 min,제1～3천；LV 60 mg/m2정맥적주2h,제1～5천,5-Fu 500 mg/m2정맥적주8h,매21천중복,2개주기이상평정료효.결과 근기료효,치료조,완전완해(CR)1례,부분완해(PR)15례,은정(SD)9례,진전(PD)5례,총유효솔CR+ PR53.3％(16/30).대조조,PR 11례,SD 11례,PD 8례,무PR병례,총유효솔36.7％(11/30).악심、구토、구강점막염、골수억제、복사급탈발위주요불량반응.량조균능내수,미발생Ⅳ도독성,골수억제대조조비치료조명현.결론 대제량LV+ 5-Fu 48 h적주연합박치료만기식관암근기료효교전통DF방안호,불량반응교소,치득진일보확대연구.
Objective To observe the effect of high-dose leucovorin(LV)plus 5-fluorouracil(5-Fu)for 48hours infusion in combination with cisplatin(DDP)in treatment of advanced esophageal cancer.Methods Pathological diagnosis of esophageal cancer 60 cases were randomly divided into treatment group of 30 patients,using DDP 25mg/m2 intravenous infusion 30 minutes,d1～3,LV 200mg/m2 intravenous infusion 2 hours,5-Fu 0.5 intravenous injection 10 minutes,and 5-Fu 2.5/m2,continuous infusion with the infusion pump for 48 hours every 21 days,2 cycles of assessment of efficacy.Control group of 30 patients,using DDP 25mg/m2 intravenous infusion 30 minutes,d1～3,LV 60mg/m2 intravenously two hours,d1～5,5-Fu 500mg/m2 intravenously 8 hours every 21 days,2 cycles of assessment of efficacy.Results Short-term effect,treatment group,complete remission(CR)1 patient and partial remission(PR)15 cases,stable(SD)9 cases,progress(PD)5 cases,the total effective rate of CR + PR53.3％(16/30).Control group,PR 11 patients,SD 11 cases,PD 8 cases,no cases of PR,the total effective rate 36.7 ％(11/30).Nausea,vomiting,oral mucositis,bone marrow suppression,diarrhea and hair loss were the main adverse reactions.Two groups are able to withstand,without any Ⅳ toxicities,myelosuppression was significant in control group than the treatment group.Conclusion High-dose LV + 5-Fu 48 hours infusion combined platinum-term efficacy in treatment of advanced esophageal cancer compared with conventional DF program is good,less adverse reactions,should further expand the study.
